Company Announcements

Syncona Limited

Total Voting Rights

1 November 2024

Pursuant to DTR 5.6.1 Syncona Limited (the "Company") announces that as at 31 October 2024 the total number of ordinary shares in issue stands at 672,214,632. The Company holds 36,943,638 ordinary shares in treasury which attract no voting rights.

Therefore, the total number of voting rights in the Company is 635,270,994. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries

Syncona Ltd

Natalie Garland-Collins / Fergus Witt
Tel: +44 (0) 20 3981 7912

Deutsche Numis

Nathan Brown

Freddie Barnfield

Tel: +44 (0) 20 7260 1000

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000 

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.